← back to search

Lynne P. Taylor

Allen Institute for Brain Science · US
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Palliative Care and End-of-Life Issues, and CNS Lymphoma Diagnosis and Treatment.
h-index
24
citations
3,557
works
97
NIH funding
primary concept
email

Recent publications

NCMP-37. Clinical patterns and long-term outcomes in stroke-like migraine attacks after radiation therapy (SMART): a case series
Neuro-Oncology 2025cited by 0position: middledoi
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Journal of Clinical Oncology 2024cited by 85position: middledoi
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors
Journal of Neuro-Oncology 2024cited by 11position: middledoi
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
JAMA Oncology 2022cited by 391position: middledoi
CTNI-56. A MULTI-INSTITUTIONAL RETROSPECTIVE SERIES OF ADULT-ONSET MEDULLOBLASTOMA
Neuro-Oncology 2022cited by 0position: lastdoi
Ethical Considerations in Dementia Diagnosis and Care
Neurology 2021cited by 41position: middledoi
A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology
JCO Oncology Practice 2020cited by 77position: middledoi
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Journal of Translational Medicine 2018cited by 538position: middledoi
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 2015cited by 1,216position: middledoi

Grants

Collaborative Research: How do biopolymers dissolve? Identification of rate-limiting steps as a framework to design polymers with tailored dissolution.
NSF2204995$306,2872022–2026PIRePORTER
Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery
NSF1309218$383,0302013–2019PIRePORTER
AIR Option 1: Technology Translation Development of a Prototype Solubility Enhancing Formulation for Improved drug Delivery using novel Cellulose Derivatives.
NSF1312157$150,0002013–2016PIRePORTER
Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery
NSF0804609$195,0002008–2013PIRePORTER

Frequent collaborators

Tresa McGranahan · Scripps Health2 papers (2022–2024)Jerome Graber · Bioengineering Center2 papers (2024–2025)Lia M. Halasz · Seattle Pacific University1 papers (2024–2024)Molly Blau · Seattle University1 papers (2024–2024)Fay J. Hlubocky · University of Illinois Chicago1 papers (2020–2020)Salvador Cruz‐Flores · The University of Texas Southwestern Medical Center1 papers (2021–2021)Leon G. Epstein · Lurie Children's Hospital1 papers (2021–2021) · 1 papers (2020–2020)Matthew P. Kirschen · Children's Hospital of Philadelphia1 papers (2021–2021)Linda D. Bosserman · Roswell Park Comprehensive Cancer Center1 papers (2020–2020)Arif H. Kamal · American Cancer Society1 papers (2020–2020)James A. Russell · University of British Columbia1 papers (2021–2021)Vyshak Alva Venur · Seattle Cancer Care Alliance1 papers (2024–2024)Ericka P. Simpson · Houston Methodist1 papers (2021–2021)Julie A. Kurek · California University of Pennsylvania1 papers (2021–2021) · 1 papers (2021–2021)Daniel G. Larriviere · Tufts University1 papers (2021–2021)Janet La · Allen Institute for Brain Science1 papers (2025–2025)Sonali M. Smith · Rutgers Cancer Institute1 papers (2020–2020)Katharina M. Busl · The University of Texas Southwestern Medical Center1 papers (2021–2021)